Plum SEC
Menu
Korean Market
Privacy Policy
Korean Market
Star Rating
Reset (View All)
★★★★★
★★★★
★★★
★★
★
★
★
★★
★★★
★★★★
★★★★★
All Disclosures
Search
EXCH
Hanall Biopharma
★
Hanall Biopharma Discloses Corporate Governance Report: No Dividends for 3 Consecutive Years, Continued Operating Loss, Long-Term Dividend Policy Established but Shareholder Returns Remain Uncertain
06/01/2026, 03:12 PM
EXCH
Hanall Biopharma
★
Notice of Investor Relations Meeting… Schedule for Communication with Investors
05/28/2026, 01:52 PM
EXCH
Hanall Biopharma
★
Conditional License Agreement for mRNA-based ERA Platform… Total $239M
05/20/2026, 05:54 PM
EXCH
Hanall Biopharma
★★★★
Q1 2026 Operating Profit Swings to Black, Revenue Up 10.7%
05/16/2026, 07:51 PM
MATR
Hanall Biopharma
★
Disposal of 66,004 Treasury Shares (0.13%) for Stock Option Exercise
05/16/2026, 07:51 PM
PERI
Hanall Biopharma
★★
HanAll BioPharma Q1 Turns to Profit, Pipeline Advances; Harbour Arbitration Risk Remains
05/15/2026, 02:54 PM
EXCH
Hanall Biopharma
★
HanAll Biopharma Major Shareholder Ownership Increases 0.04%
05/06/2026, 04:30 PM
OWNR
Hanall Biopharma
★
No Change in Executive/Major Shareholder Holdings
05/06/2026, 04:37 PM
OTHR
Hanall Biopharma
★
Hanall Biopharma Completes Disposal of 66,004 Treasury Shares
05/06/2026, 04:50 PM
OWNR
Hanall Biopharma
★
Filing of Report on Ownership of Specific Securities by Executives and Major Shareholders (No Changes)
05/06/2026, 04:44 PM
OWNR
Hanall Biopharma
★
No Material Changes in Executive/Major Shareholder Ownership Report
05/06/2026, 04:40 PM